Clinical trial

Select the Appropriate Population for Adding CDK4/6i to Neoadjuvant Endocrine Therapy

NCT05809024

StatusUNKNOWN

Study typeINTERVENTIONAL

Start date2023-03-01

PhasePHASE4

Study timeline

Study start (actual)2023-03-01Date precision: day

Registry last updated2023-04-12

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Locally Advanced Breast Cancerunresolved

Hormone Receptor Positive，HER2-negative Breast Cancerunresolved

Interventions

letrozoleDRUG · verified · RxNorm: letrozole

Sponsors & collaborators

Yongsheng Wanglead sponsor

Jiangsu HengRui Medicine Co., Ltd.collaborator

Mapped research locations

JinanShandong, China1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05809024 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.